Sermorelin (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Sermorelin is a synthetic 29-amino-acid fragment corresponding to the biologically active portion of human growth-hormone-releasing hormone (GHRH 1–29). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of approximately 3.33 mg/mL (3,330 mcg/mL). At that fill, one unit on a U-100 insulin syringe corresponds to roughly 33.3 mcg, so a 300 mcg measurement reads as about 9 units (0.09 mL). Because the daily amounts are small, a 30-unit or 50-unit syringe improves draw precision during the lower-dose weeks.

Standard (Gradual) Titration Schedule

The gradual schedule steps the nightly amount upward every two weeks, which mirrors the slow-escalation pattern used to settle tolerability before reaching the upper end of the adult research band.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Pediatric-Reference (Weight-Based) Schedule

The pediatric growth-hormone-deficiency literature used a weight-based nightly dose rather than the fixed adult steps above. The table below converts the published 30 mcg/kg figure to syringe units at the same 3.33 mg/mL fill, for reference only.

Supplies Needed

• Sermorelin vials (10 mg): ~2 vials for a full 8-week nightly gradual run; budget more for the 3–6 month adult research windows.
• Insulin syringes (U-100, 1 mL): a 56–100 count box for an 8-week nightly schedule (one fresh syringe per draw). Consider 30- or 50-unit barrels for the low-dose weeks.
• Bacteriostatic water (10 mL): one bottle reconstitutes ~3 vials at 3 mL each.
• Alcohol swabs: roughly two 100-count boxes for a nightly 8-week run.
• Sharps container: one approved disposal container.

Protocol Overview

• Research goal: model endogenous, pulsatile GH release via GHRH-receptor stimulation rather than exogenous GH replacement.
• Schedule: once-daily subcutaneous administration at bedtime in the published model.
• Dose band: 200–500 mcg nightly (adult research); 30 mcg/kg nightly (pediatric reference).
• Fill: 10 mg lyophilized, reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: 2–8 °C dry and 2–8 °C reconstituted; do not freeze.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and hold each level for about two weeks before escalating.
• Time administration at bedtime to align with the natural nocturnal GH pulse modelled in the literature.
• Keep a fixed daily cadence for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.

Storage Instructions

Keep sealed lyophilized vials refrigerated at 2–8 °C, dry and protected from light. Once reconstituted, continue to refrigerate at 2–8 °C and use within about 10–14 days. Do not freeze the reconstituted solution. Allow refrigerated material to warm slightly before drawing, avoid freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Keep the stopper intact and wiped with alcohol before each entry.
• Use a low-volume barrel (30 or 50 units) for the small nightly draws to improve precision.
• Document each draw — date, volume, remaining material — for reproducibility.

How Sermorelin Works

Sermorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH 1–29) that binds GHRH receptors on the somatotrope cells of the anterior pituitary, prompting the gland to secrete its own growth hormone in a pulsatile, physiologic pattern. Because the upstream signal is preserved, normal negative-feedback controls — somatostatin tone and IGF-1 feedback — stay intact, which in the published model limits the supraphysiologic GH and IGF-1 spikes associated with directly administered exogenous growth hormone. This indirect, feedback-respecting mechanism is what distinguishes a GHRH analog like Sermorelin from injected recombinant GH.

Reported Benefits & Side Effects

Benefits observed in research

• Stimulation of endogenous, pulsatile GH release with corresponding physiologic IGF-1 elevation.
• Measurable improvements in height velocity and growth parameters over 6–12 months in pediatric GH-deficiency studies.
• Reported changes in body composition, energy, recovery and metabolic markers in adult off-label contexts, though that evidence base is limited.
• Retention of physiologic feedback, reducing supraphysiologic exposure relative to exogenous GH.

Side effects reported

• Injection-site reactions were the most common finding (~17%): transient redness, pain or swelling.
• Rare systemic effects (<1%) included headache, flushing, dizziness, hyperactivity, drowsiness and hives.
• Roughly 6.5% developed subclinical hypothyroidism in one study.
• No serious acromegaly, hypoglycemia or excessive IGF-1 elevations were reported at the studied dosages.

Supporting Lifestyle Factors (Research Context)

• Adequate, consistent sleep, since the bedtime cadence is built around the nocturnal GH pulse.
• Protein-forward nutrition and resistance training as standard controls in body-composition study designs.
• Stress management and hydration as routine trial controls.

Injection Technique (Reference Only)

• Select a subcutaneous site — abdomen, thigh, upper arm or buttocks — and rotate systematically with 1–2 inch spacing.
• Clean the vial stopper and the skin with alcohol swabs and let both dry.
• Insert at a 45–90° angle into the subcutaneous fat layer; aspiration is not required for subcutaneous work.
• Inject slowly over a couple of seconds, pause briefly, then withdraw and apply gentle pressure without rubbing.
• Dispose of the needle and syringe in an approved sharps container; never recap a used needle.

References

Related Protocols